Video: Latest Treatment for Hep C.

Amlodipine Besylate

Pronunciation

Class: Dihydropyridines
VA Class: CV200
CAS Number: 111470-99-6
Brands: Azor (combination), Caduet, Exforge (combination), Lotrel, Norvasc

Introduction

Amlodipine is a calcium-channel blocking agent; a dihydropyridine derivative with an intrinsically long duration of action.1 2 3

Uses for Amlodipine Besylate

Hypertension

Amlodipine is used for management of hypertension (alone or in combination with other classes of antihypertensive agents);1 2 3 4 5 6 12 21 49 112 113 may be used in fixed combination with benazepril, olmesartan, or valsartan when such combined therapy is indicated.21 112 113

Calcium-channel blocking agents are one of several preferred initial therapies in hypertensive patients with a high risk of developing CAD, including those with diabetes mellitus;82 in geriatric patients with isolated systolic hypertension;49 53 and in patients with coexisting angina.12 49

Slideshow: Can Prescription Drugs Lead to Weight Gain?

Amlodipine can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.82

Amlodipine should not be used for acute management of hypertensive crises.1 7 8 12 49

Addition of benazepril to amlodipine usually does not provide additional antihypertensive effects in blacks but appears to reduce development of amlodipine-associated edema regardless of race.21

May use amlodipine/atorvastatin fixed-combination preparation when treatment with both amlodipine (for hypertension) and atorvastatin (for dyslipidemias and prevention of cardiovascular events) is appropriate.107

CAD

Amlodipine is used for management of Prinzmetal variant angina and chronic stable angina pectoris;1 2 3 4 7 8 9 has been used alone or in combination with other antianginal agents.1 2 3 4 9 Calcium-channel blockers are considered the drugs of choice in management of Prinzmetal variant angina.b

Amlodipine is used in patients with recently documented CAD (by angiography) and without heart failure or an ejection fraction <40% to reduce the risk of coronary revascularization procedure and hospitalization due to angina.1

May use amlodipine/atorvastatin fixed-combination preparation when treatment with both amlodipine (for CAD) and atorvastatin (for dyslipidemias and prevention of cardiovascular events) is appropriate.107

Amlodipine Besylate Dosage and Administration

General

Hypertension

  • Manufacturers state that amlodipine/benazepril and amlodipine/olmesartan fixed-combination preparations should not be used for initial treatment of hypertension.21 112

  • Fixed-combination amlodipine/valsartan tablets may be used for initial treatment of hypertension in patients likely to require combination therapy with multiple antihypertensive agents to control BP.113 Consider potential benefits and risks of initiating therapy with the fixed combination of amlodipine and valsartan, including whether the patient is likely to tolerate the lowest available dosage of the combined drugs.113

  • If the patient’s baseline BP is 160/100 mm Hg, the estimated probability of achieving SBP control (SBP <140 mm Hg) is 47, 67, or 80% and of achieving DBP control (DBP <90 mm Hg) is 62, 80, or 85% with valsartan alone, amlodipine alone, or amlodipine combined with valsartan, respectively.113

Administration

Oral Administration

Administer amlodipine orally without regard to meals.1 2 3 5

Dosage

Amlodipine is available as amlodipine besylate; dosage expressed in terms of amlodipine.1

Pediatric Patients

Hypertension
Amlodipine Therapy for Hypertension
Oral

Children ≥6 years of age: Usual effective amlodipine dosage is 2.5–5 mg once daily.1 105

Adults

Hypertension
Amlodipine Therapy for Hypertension
Oral

Initially as monotherapy, amlodipine 2.5–5 mg once daily.1 2 4 6 49 In small or frail individuals, initiate therapy with 2.5 mg once daily.1

When adding amlodipine to an existing antihypertensive regimen, use initial dosage of 2.5 mg once daily.1

Increase amlodipine dosage gradually over 7–14 days until optimum control of BP is obtained (up to a maximum dosage of 10 mg daily).1 May increase more rapidly if symptoms so warrant and patient’s tolerance and response are frequently assessed.1

Usual maintenance dosage of amlodipine is 5–10 mg once daily.1 2 6 12 49

Amlodipine/Benazepril Fixed-combination Therapy for Hypertension
Oral

In studies using amlodipine/benazepril fixed combination in dosages of amlodipine 2.5–10 mg daily and benazepril hydrochloride 10–40 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.21

If BP is not adequately controlled by monotherapy with amlodipine (or another dihydropyridine-derivative calcium-channel blocker) or benazepril (or another ACE inhibitor), can switch to amlodipine/benazepril fixed combination.21

If BP is adequately controlled by monotherapy with amlodipine, but edema has developed, can switch to amlodipine/benazepril fixed combination to achieve similar or better BP control without edema.21 May be prudent to reduce amlodipine dosage, especially in nonblack patients, when benazepril is initiated to avoid excessive antihypertensive response.21

If BP is controlled with amlodipine and benazepril (administered separately), can switch to the fixed-combination preparation containing the corresponding individual doses for convenience.21

Adjust dosage of amlodipine/benazepril fixed combination according to patient’s response; consider that steady-state plasma concentrations of amlodipine and benazepril are reached after 7 and 2 days, respectively.21

In small or frail patients, initial amlodipine dosage of 2.5 mg (available in fixed combination with benazepril hydrochloride 10 mg) once daily.21

Amlodipine/Olmesartan Fixed-combination Therapy for Hypertension
Oral

If BP is not adequately controlled by monotherapy with amlodipine (or another dihydropyridine-derivative calcium-channel blocker) or olmesartan (or another angiotensin II receptor antagonist), can switch to the fixed-combination preparation containing amlodipine 5 mg and olmesartan medoxomil 20 or 40 mg or, alternatively, amlodipine 10 mg and olmesartan medoxomil 20 or 40 mg.112

Can use the fixed combination as a substitute for the individually titrated drugs.112 Can switch to the fixed-combination preparation containing the corresponding individual doses of amlodipine and olmesartan; alternatively, can increase the dosage of one or both components for additional antihypertensive effects.112

Adjust dosage of amlodipine/olmesartan fixed combination, up to a maximum dosage of amlodipine 10 mg daily and olmesartan medoxomil 40 mg daily, according to patient’s response after ≥2 weeks at the current dosage.112

Amlodipine/Valsartan Fixed-combination Therapy for Hypertension
Oral

In studies using amlodipine/valsartan fixed combination in dosages of amlodipine 5–10 mg daily and valsartan 160–320 mg daily, BP response increased with increasing dosages of the drugs.113

If BP is not adequately controlled by monotherapy with amlodipine (or another dihydropyridine-derivative calcium-channel blocker) or valsartan (or another angiotensin II receptor antagonist), can switch to the fixed-combination preparation containing amlodipine 5 mg and valsartan 160 or 320 mg or, alternatively, amlodipine 10 mg and valsartan 160 or 320 mg.113

If dose-limiting adverse effects have developed during monotherapy with amlodipine or valsartan, can switch to a fixed-combination preparation containing a lower dose of that drug to achieve similar BP control; adjust dosage according to patient’s response after 3–4 weeks of therapy.113

If BP is controlled with amlodipine and valsartan (administered separately), can switch to the fixed-combination preparation containing the corresponding individual doses for convenience.113

When used for initial therapy of hypertension in patients likely to require combination therapy with multiple antihypertensive agents, recommended initial dosage is amlodipine 5 mg and valsartan 160 mg daily in those who are not volume depleted.113

Increase to maximum dosage of amlodipine 10 mg and valsartan 320 mg daily, if needed, to control BP.113 May adjust dosage at intervals of 1–2 weeks, since most of the antihypertensive effect of a given dosage is achieved within 2 weeks after a change in dosage.113

Amlodipine/Atorvastatin Fixed-combination Therapy for Hypertension (Amlodipine) and for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin)
Oral

Use the fixed combination as a substitute for the individually titrated drugs.107 Can switch to the fixed-combination preparation containing the corresponding individual doses of amlodipine and atorvastatin; alternatively, can increase the dosage of one or both components for additional antihypertensive and/or antilipemic effects.107

Use the fixed combination to provide additional therapy for patients currently receiving one component of the preparation.107 Select initial dosage of the fixed combination based on the current dosage of the component being used and the recommended initial dosage for the added monotherapy.107

Use the fixed combination to initiate treatment in patients requiring therapy for hypertension and dyslipidemias.107 Select initial dosage of the fixed combination based on recommended dosages of the individual components.107

CAD
Amlodipine Therapy for Angina
Oral

Usual amlodipine dosage is 5–10 mg once daily;1 2 adequate control usually requires a maintenance dosage of 10 mg daily.1

Amlodipine Therapy for Angiographically Documented CAD
Oral

Recommended amlodipine dosage is 5–10 mg once daily;1 adequate control usually requires a maintenance dosage of 10 mg daily.1

Amlodipine/Atorvastatin Fixed-combination Therapy for CAD (Amlodipine) and for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin)
Oral

Use the fixed combination as a substitute for the individually titrated drugs.107 Can switch to the fixed-combination preparation containing the corresponding individual doses of amlodipine and atorvastatin; alternatively, can increase the dosage of one or both components for additional antianginal and/or antilipemic effects.107

Use the fixed combination to provide additional therapy for patients currently receiving one component of the preparation.107 Select initial dosage of the fixed combination based on the current dosage of the component being used and the recommended initial dosage for the added monotherapy.107

Use the fixed combination to initiate treatment in patients requiring therapy for angina and dyslipidemias.107 Select initial dosage of the fixed combination based on recommended dosages of the individual components.107

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Children ≥6 years of age: Safety and efficacy of amlodipine dosages >5 mg daily not established.1

Adults

Hypertension
Oral

Maximum 10 mg of amlodipine once daily.1 107 112 113

Special Populations

The following information addresses dosage of amlodipine in special populations. Dosages of drugs administered in fixed combination with amlodipine also may require adjustment in certain patient populations; the need for such dosage adjustments must be considered in the context of cautions, precautions, and contraindications specific to that population and drug.21 107 112 113

Hepatic Impairment

Hypertension

Initially, amlodipine 2.5 mg daily (as initial or add-on therapy).1 21 107 112

Angina

Initially, amlodipine 5 mg daily.1 107

Renal Impairment

Amlodipine dosage modification not necessary.1 2 3 5 112 113

Preparations containing amlodipine in fixed combination with benazepril are not recommended in patients with Clcr ≤30 mL/minute or Scr >3 mg/dL.21

Geriatric Patients

Hypertension

Initially, amlodipine 2.5 mg daily (as initial or add-on therapy).1 21 107 112 113 Adjust subsequent dosage based on patient response and tolerance.1

Angina

Initially, amlodipine 5 mg daily.1 107

Cautions for Amlodipine Besylate

Contraindications

  • Known hypersensitivity to amlodipine.1 21 107

  • When amlodipine is used in fixed combination with atorvastatin, benazepril, olmesartan, or valsartan, consider contraindications associated with the concomitant agent.21 107 112 113

Warnings/Precautions

Warnings

Increased Angina and/or AMI

Rarely, increased frequency, duration, and/or severity of angina or AMI, particularly in patients with severe obstructive CAD, upon initiation or dosage increase of calcium-channel blockers.1

General Precautions

Use of Fixed Combinations

When amlodipine is used in fixed combination with atorvastatin, benazepril, olmesartan, or valsartan, consider cautions, precautions, contraindications, and interactions associated with the concomitant agent.21 107 112 113 Consider cautionary information applicable to specific populations (e.g., pregnant or nursing women, individuals with hepatic or renal impairment, geriatric patients) for each drug in the fixed combination.21 107 112 113

Hypotension

Possible acute hypotension.1 Use amlodipine with caution, particularly in patients with severe aortic stenosis.1

CHF

Use amlodipine with caution in patients with CHF; no adverse effects on survival, cardiac morbidity, or worsened heart failure reported in controlled studies.1

Specific Populations

Pregnancy

Category C.1

Lactation

Not known whether amlodipine is distributed into milk; manufacturer recommends discontinuance of nursing if amlodipine is used.1

Pediatric Use

Safety and efficacy of amlodipine in children <6 years of age not established.1

Safety and efficacy of amlodipine in fixed combination with atorvastatin, benazepril, olmesartan, or valsartan not established in children.21 107 112 113

Geriatric Use

Select amlodipine dosage with caution; initiate with dosage at lower end of recommended range.1 21 112 113 (See Geriatric Patients under Dosage and Administration and see Special Populations under Pharmacokinetics.)

Amlodipine in fixed combination with benazepril, olmesartan, or valsartan: No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.21 112 113

Amlodipine in fixed combination with atorvastatin: Safety and efficacy not established in geriatric patients.107

Hepatic Impairment

Use amlodipine with caution and consider dosage reduction in patients with severe hepatic impairment.1 21 112 113 (See Hepatic Impairment under Dosage and Administration and see Special Populations under Pharmacokinetics.)

Common Adverse Effects

Amlodipine: Headache, edema.1 Edema may be less frequent with concomitant benazepril or olmesartan therapy.21 112

Interactions for Amlodipine Besylate

The following information addresses potential interactions with amlodipine. When amlodipine is used in fixed combination with atorvastatin, benazepril, olmesartan, or valsartan, consider interactions associated with the concomitant agent.21 107 112 113

Specific Drugs and Food

Drug or Food

Interaction

Alcohol

No change in alcohol pharmacokinetics1

Antacids (e.g., aluminum hydroxide and magnesium hydroxide)

Pharmacokinetic interaction unlikely1

Atorvastatin

No clinically important change in atorvastatin pharmacokinetics1

Cimetidine

Pharmacokinetic interaction unlikely1

Digoxin

No effects on serum digoxin concentrations or clearance1

Grapefruit juice

Altered bioavailability possible;64 65 74 75 no clinically important changes in another study1

Sildenafil

Pharmacokinetic interaction unlikely; additional reduction of BP possible1

Warfarin

No change in PT1

Amlodipine Besylate Pharmacokinetics

Absorption

Bioavailability

Peak plasma amlodipine concentrations attained 6–12 hours after oral administration.1 Absolute bioavailability ranges from 64–90%.1

Duration

Antihypertensive effects of amlodipine persist for at least 24 hours after administration.1

Food

Food does not affect bioavailability of amlodipine besylate tablets.1

Distribution

Extent

Not known whether amlodipine is distributed into milk.1

Plasma Protein Binding

Amlodipine: Approximately 93%.1

Elimination

Metabolism

Amlodipine is extensively metabolized to inactive metabolites in the liver.1

Elimination Route

Amlodipine is excreted in urine as metabolites (60%) and unchanged drug (10%).1

Half-life

Terminal elimination half-life of amlodipine is 30–50 hours.1

Special Populations

In geriatric patients, amlodipine clearance decreased and AUC increased about 40–60%.1

In patients with hepatic impairment, amlodipine clearance decreased and AUC increased about 40–60%.1

In patients with moderate to severe heart failure, amlodipine clearance decreased and AUC increased about 40–60%.1

Stability

Storage

Oral

Tablets

Amlodipine: Tight, light-resistant containers at 15–30°C.1

Amlodipine/atorvastatin, amlodipine/olmesartan, and amlodipine/valsartan fixed combinations: 25°C (may be exposed to 15–30°C).107 112 113

Capsules

Amlodipine/benazepril fixed combination: Tight container at 25ºC (may be exposed to 15–30ºC).21

Actions

  • Amlodipine inhibits transmembrane influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells, without changing serum calcium concentrations.1

  • Amlodipine is a peripheral arterial vasodilator; acts directly on vascular smooth muscle causing reduction in peripheral vascular resistance and BP.1

  • Amlodipine reduces total peripheral resistance (afterload) and rate pressure product and thus myocardial oxygen demand at any given level of exercise in patients with exertional angina.1

  • Amlodipine blocks constriction and restores blood flow in coronary arteries in response to calcium, potassium, epinephrine, serotonin, and thromboxane A2 analog in animal studies and human vessels in vitro.1

Advice to Patients

  • When amlodipine is used in fixed combination with atorvastatin, benazepril, olmesartan, or valsartan, importance of informing patients of important cautionary information about the concomitant agent.21 107 112 113

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Amlodipine Besylate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

2.5 mg (of amlodipine)*

Amlodipine Besylate Tablets

Norvasc

Pfizer

5 mg (of amlodipine)*

Amlodipine Besylate Tablets

Norvasc

Pfizer

10 mg (of amlodipine)*

Amlodipine Besylate Tablets

Norvasc

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Amlodipine Besylate Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

2.5 mg (of amlodipine) with Benazepril Hydrochloride 10 mg*

Amlodipine Besylate and Benazepril Hydrochloride Capsules (combination)

Lotrel

Novartis

5 mg (of amlodipine) with Benazepril Hydrochloride 10 mg*

Amlodipine Besylate and Benazepril Hydrochloride Capsules (combination)

Lotrel

Novartis

5 mg (of amlodipine) with Benazepril Hydrochloride 20 mg*

Amlodipine Besylate and Benazepril Hydrochloride Capsules (combination)

Lotrel

Novartis

5 mg (of amlodipine) with Benazepril Hydrochloride 40 mg

Lotrel

Novartis

10 mg (of amlodipine) with Benazepril Hydrochloride 20 mg*

Amlodipine Besylate and Benazepril Hydrochloride Capsule (combination)

Lotrel

Novartis

10 mg (of amlodipine) with Benazepril Hydrochloride 40 mg

Lotrel

Novartis

Tablets

5 mg (of amlodipine) with Olmesartan Medoxomil 20 mg

Azor

Daiichi-Sankyo

5 mg (of amlodipine) with Olmesartan Medoxomil 40 mg

Azor

Daiichi-Sankyo

10 mg (of amlodipine) with Olmesartan Medoxomil 20 mg

Azor

Daiichi-Sankyo

10 mg (of amlodipine) with Olmesartan Medoxomil 40 mg

Azor

Daiichi-Sankyo

Tablets, film-coated

2.5 mg (of amlodipine) with Atorvastatin Calcium 10 mg (of atorvastatin)

Caduet

Pfizer

2.5 mg (of amlodipine) with Atorvastatin Calcium 20 mg (of atorvastatin)

Caduet

Pfizer

2.5 mg (of amlodipine) with Atorvastatin Calcium 40 mg (of atorvastatin)

Caduet

Pfizer

5 mg (of amlodipine) with Atorvastatin Calcium 10 mg (of atorvastatin)

Caduet

Pfizer

5 mg (of amlodipine) with Atorvastatin Calcium 20 mg (of atorvastatin)

Caduet

Pfizer

5 mg (of amlodipine) with Atorvastatin Calcium 40 mg (of atorvastatin)

Caduet

Pfizer

5 mg (of amlodipine) with Atorvastatin Calcium 80 mg (of atorvastatin)

Caduet

Pfizer

5 mg (of amlodipine) with Valsartan 160 mg

Exforge

Novartis

5 mg (of amlodipine) with Valsartan 320 mg

Exforge

Novartis

10 mg (of amlodipine) with Atorvastatin Calcium 10 mg (of atorvastatin)

Caduet

Pfizer

10 mg (of amlodipine) with Atorvastatin Calcium 20 mg (of atorvastatin)

Caduet

Pfizer

10 mg (of amlodipine) with Atorvastatin Calcium 40 mg (of atorvastatin)

Caduet

Pfizer

10 mg (of amlodipine) with Atorvastatin Calcium 80 mg (of atorvastatin)

Caduet

Pfizer

10 mg (of amlodipine) with Valsartan 160 mg

Exforge

Novartis

10 mg (of amlodipine) with Valsartan 320 mg

Exforge

Novartis

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Amlodipine Besy-Benazepril HCl 10-20MG Capsules (SANDOZ): 30/$89.99 or 90/$259.97

Amlodipine Besy-Benazepril HCl 10-40MG Capsules (SANDOZ): 30/$115.99 or 90/$319.98

Amlodipine Besy-Benazepril HCl 2.5-10MG Capsules (LUPIN PHARMACEUTICALS): 30/$69.99 or 90/$199.96

Amlodipine Besy-Benazepril HCl 5-10MG Capsules (SANDOZ): 30/$76.99 or 90/$215.96

Amlodipine Besy-Benazepril HCl 5-20MG Capsules (DR.REDDY'S LABORATORIES): 30/$82.99 or 90/$229.96

Amlodipine Besy-Benazepril HCl 5-40MG Capsules (SANDOZ): 30/$115.99 or 90/$319.96

AmLODIPine Besylate 10MG Tablets (GREENSTONE): 90/$23.99 or 180/$36.97

AmLODIPine Besylate 2.5MG Tablets (MYLAN): 90/$19.99 or 100/$21.97

AmLODIPine Besylate 5MG Tablets (GREENSTONE): 90/$22.99 or 180/$37.96

Amlodipine-Atorvastatin 10-10MG Tablets (RANBAXY PHARMACEUTICALS): 30/$140.00 or 90/$395.96

Amlodipine-Atorvastatin 10-20MG Tablets (RANBAXY PHARMACEUTICALS): 30/$169.99 or 90/$479.95

Amlodipine-Atorvastatin 10-40MG Tablets (RANBAXY PHARMACEUTICALS): 30/$159.98 or 90/$459.98

Amlodipine-Atorvastatin 5-10MG Tablets (RANBAXY PHARMACEUTICALS): 30/$140.00 or 90/$395.96

Amlodipine-Atorvastatin 5-20MG Tablets (RANBAXY PHARMACEUTICALS): 30/$169.99 or 90/$479.95

Amlodipine-Atorvastatin 5-40MG Tablets (RANBAXY PHARMACEUTICALS): 30/$180.00 or 90/$479.95

Amturnide 300-10-25MG Tablets (NOVARTIS): 30/$109.99 or 90/$305.96

Azor 10-20MG Tablets (SANKYO): 30/$117.76 or 90/$340.05

Azor 10-40MG Tablets (SANKYO): 90/$442.99 or 270/$1,299.02

Azor 5-20MG Tablets (SANKYO): 30/$121.06 or 90/$349.97

Azor 5-40MG Tablets (SANKYO): 30/$154.35 or 90/$450.93

Caduet 10-10MG Tablets (PFIZER U.S.): 30/$167.98 or 90/$474.95

Caduet 10-20MG Tablets (PFIZER U.S.): 30/$226.99 or 90/$654.96

Caduet 10-40MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$651.99

Caduet 10-80MG Tablets (PFIZER U.S.): 30/$227.89 or 90/$620.05

Caduet 2.5-10MG Tablets (PFIZER U.S.): 30/$162.45 or 90/$470.56

Caduet 2.5-20MG Tablets (PFIZER U.S.): 30/$226.00 or 90/$635.99

Caduet 2.5-40MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$639.99

Caduet 5-10MG Tablets (PFIZER U.S.): 30/$162.99 or 90/$458.96

Caduet 5-20MG Tablets (PFIZER U.S.): 30/$224.00 or 90/$636.95

Caduet 5-40MG Tablets (PFIZER U.S.): 30/$218.00 or 90/$621.98

Caduet 5-80MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$650.96

Exforge 10-160MG Tablets (NOVARTIS): 30/$135.99 or 90/$375.99

Exforge 10-320MG Tablets (NOVARTIS): 30/$169.99 or 90/$485.97

Exforge 5-160MG Tablets (NOVARTIS): 30/$119.99 or 90/$341.97

Exforge 5-320MG Tablets (NOVARTIS): 30/$151.00 or 90/$433.98

Exforge HCT 10-160-12.5MG Tablets (NOVARTIS): 30/$128.99 or 90/$372.95

Exforge HCT 5-160-12.5MG Tablets (NOVARTIS): 30/$117.99 or 90/$341.97

Exforge HCT 5-160-25MG Tablets (NOVARTIS): 30/$119.99 or 90/$339.99

Lotrel 10-20MG Capsules (NOVARTIS): 30/$158.99 or 90/$461.99

Lotrel 10-40MG Capsules (NOVARTIS): 30/$175.00 or 90/$499.97

Lotrel 2.5-10MG Capsules (NOVARTIS): 30/$123.99 or 90/$345.98

Lotrel 5-10MG Capsules (NOVARTIS): 30/$127.99 or 90/$350.96

Lotrel 5-10MG Capsules (NOVARTIS): 30/$139.99 or 90/$399.96

Lotrel 5-40MG Capsules (NOVARTIS): 30/$145.98 or 90/$426.95

Norvasc 10MG Tablets (PFIZER U.S.): 30/$107.99 or 90/$299.96

Norvasc 2.5MG Tablets (PFIZER U.S.): 30/$80.99 or 90/$220.96

Norvasc 5MG Tablets (PFIZER U.S.): 30/$80.99 or 90/$225.96

Tekamlo 300-10MG Tablets (NOVARTIS): 30/$119.99 or 90/$339.98

Tribenzor 20-5-12.5MG Tablets (SANKYO): 30/$119.99 or 90/$335.95

Tribenzor 40-10-25MG Tablets (SANKYO): 30/$152.14 or 90/$433.29

Tribenzor 40-5-12.5MG Tablets (SANKYO): 30/$152.14 or 60/$304.27

Tribenzor 40-5-25MG Tablets (SANKYO): 30/$154.49 or 90/$444.01

Twynsta 80-5MG Tablets (BOEHRINGER INGELHEIM): 30/$129.99 or 90/$365.98

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 1, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Pfizer Laboratories. Norvasc (amlodipine besylate) tablets prescribing information. New York; 2006 Aug.

2. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991; 41:478-505. [PubMed 1711448]

3. Burges RA, Dodd MG. Amlodipine. Cardiovasc Drug Rev. 1990; 8:25-44.

4. Anon. Amlodipine—a new calcium-channel blocker. Med Lett Drugs Ther. 1992; 34:99-100. [PubMed 1406450]

5. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992; 22:22-31. [PubMed 1532771]

6. Julius S. Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol. 1988; 12(Suppl 7):S27-33.

7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-57. [IDIS 184763] [PubMed 6143542]

8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. [IDIS 242588] [PubMed 3365073]

9. DiBianco R, Schoomaker FW, Singh JB et al. Amlodipine combined with beta blockade for chronic angina: results of a multicenter, placebo-controlled, randomized double-blind study. Clin Cardiol. 1992; 15:519-24. [PubMed 1354085]

10. Thadani U and the Amlodipine Study Group. Amlodipine: A once-daily calcium antagonist in the treatment of angina pectoris—a parallel dose-response, placebo controlled study. Am Heart J. 1989; 118(5 Part 2):1135. [IDIS 305825] [PubMed 2530876]

11. Taylor SH, Lee P, Jackson N et al. A four-week double-blind, placebo-controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris. Am Heart J. 1989; 118(5 Part 2):1133-4. [IDIS 305824] [PubMed 2530875]

12. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. [IDIS 309043] [PubMed 8422206]

13. Sandoz Pharmaceuticals Corp. DynaCirc (isradipine) capsules prescribing information. East Hanover, NJ; 1992 Jun.

14. Lopez LM, Santiago TM. Isradipine—another calcium-channel blocker for the treatment of hypertension and angina. Ann Pharmacother. 1992; 26:789-99. [IDIS 298260] [PubMed 1535246]

15. Fitton A, Benfield P. Isradipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1990; 40:31-74. [PubMed 2143980]

16. Walton T, Symes LR. Felodipine and isradipine: new calcium-channel blocking agents for the treatment of hypertension. Clin Pharm. 1993; 12:261-75. [IDIS 311530] [PubMed 8458178]

17. Prisant LM, Carr AA, Nelson EB et al. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives: a multicenter evaluation. Arch Intern Med. 1989; 149:2453-7. [IDIS 260612] [PubMed 2530945]

18. Anon. Isradipine for hypertension. Med Lett Drugs Ther. 1991; 33:51-4. [PubMed 1827655]

19. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

20. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. [PubMed 8422205]

21. Novartis. Lotrel (amlodipine besylate and benazepril hydrochloride) capsules prescribing information. East Hanover, NJ; 2007 Jun.

22. Glasser SP, Clark PI, Lipicky RJ et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. 1991; 265:1550-4. [PubMed 1671885]

23. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

24. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

25. Anon. NHLBI panel stands by JNC V in response to Circulation CCB article; AIM report supports use of beta blockers for prevention of sudden cardiac death. F-D- C Rep. 1995; 57(Sep 4):3-4.

26. American Heart Association. Public advisory statement on calcium channel blocker drugs. Dallas, TX; 1995 Aug 28.

27. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. [IDIS 352203] [PubMed 7637142]

28. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of incident myocardial infarction associated with anti- hypertensive drug therapies. Circulation. 1995; 91:925.

29. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995; 274:654-5. [IDIS 352205] [PubMed 7637148]

30. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326-31. [IDIS 353358] [PubMed 7648682]

31. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 1995; 92:1068-73. [IDIS 353353] [PubMed 7648646]

32. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 1995; 92:1074-8. [IDIS 353354] [PubMed 7648647]

33. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

34. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 1995; 91:2855-6. [PubMed 7796490]

35. Habib GB. Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest. 1995; 108:3-5. [IDIS 351406] [PubMed 7606987]

36. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet. 1995; 346:586-7. [IDIS 353102] [PubMed 7650997]

37. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991; 67:1295-7. [IDIS 284079] [PubMed 2035457]

38. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 1993; 71:177-83. [IDIS 308552] [PubMed 8421980]

39. Wagenknecht LE, Furberg CD, Hammon JW et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995; 310:776-7. [IDIS 345035] [PubMed 7711582]

40. Miles Inc. American Heart Association, Dr. Psalty and Miles Inc. release statements qualifying possible risks of calcium channel blockers. West Haven, CT; 1995 Mar 15. Press release.

41. Dear healthcare professional letter regarding calcium-channel blockers and increased risk of heart attack. Chicago:Searle. 1995 Mar 17.

42. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma Wkly. 1994; Apr 9:4.

43. Anon. Groups act to dispel concerns about calcium-channel blockers. Am J Health- Syst Pharm. 1995; 52:1154, 58. [PubMed 7656105]

44. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991; 84:2598-600. [IDIS 295953] [PubMed 1959210]

45. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 1995; 123:888-9. [IDIS 356631] [PubMed 7486476]

46. Reviewers’ comments (personal observations).

47. Pratt Pharmacueticals. Procardia (nifedipine) capsules prescribing information (dated 1993 Feb). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:1906-7.

48. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989; 299:1187-92. [IDIS 260789] [PubMed 2513047]

49. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

50. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]

51. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. [IDIS 380501] [PubMed 9042847]

52. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428. [IDIS 376249] [PubMed 8890834]

53. Staessen JA, Fagard R, Thijs L et al. for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997; 350:757-64. [IDIS 392056] [PubMed 9297994]

54. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996; 45:216-22. [IDIS 362953] [PubMed 8549868]

55. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52. [IDIS 400553] [PubMed 9486993]

56. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998; 351:689-90. [IDIS 409001] [PubMed 9504510]

57. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients

58. Byington RP, Craven TE, Furberg CD et al. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet. 1997; 350:1075-6. [IDIS 393279] [PubMed 10213554]

59. Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet. 1998; 351:216-7. [IDIS 398935] [PubMed 9449897]

60. Josefson D. Infarction risk found with calcium channel blocker. BMJ. 1998; 316:797.

61. Cutler JA. Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med. 1998; 338:679-81. [IDIS 400554] [PubMed 9486999]

62. Bayer, West Haven, CT: Personal communication.

63. Bakris GL, Copley JB, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996; 50:1641-50. [PubMed 8914031]

64. Joseffson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokineitcs of amlodipine. Eur J Clin Pharmacol. 1996; 51:189-93. [IDIS 376224] [PubMed 8911887]

65. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997; 33:103-21. [PubMed 9260034]

66. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87. [IDIS 398865] [PubMed 9465845]

67. Spence JD. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87-8. [IDIS 398865] [PubMed 9465845]

68. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokin. 1994; 26:91-8.

69. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. [IDIS 490723] [PubMed 12479770]

70. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]

71. Pahor M, Psaty BM, Alderman MH et al. Health outcomes associated with calcium channel antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized control trails. Lancet. 2000; 356:1949-54. [IDIS 456765] [PubMed 11130522]

72. Blood Pressure Lowering Treatment Trialists&#x2019; Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000; 355:1955-64. [PubMed 10859041]

73. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356:366-72. [IDIS 451430] [PubMed 10972368]

74. Vincent J, Harris SI, Foulds G et al. Lack of effect on grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000; 50:455-63. [IDIS 457324] [PubMed 11069440]

75. Vincent J, Harris S, Foulds G et al. Amlodipine and grapefruit juice. Br J Clin Pharmacol. 2002; 53:406. Letter

76. Riley LJ Jr, Vlasses PH, Ferguson RK. Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril. Am Heart J. 1985; 109:1085-9. [IDIS 200003] [PubMed 2986440]

77. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part 2: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200. [IDIS 394161] [PubMed 4034407]

78. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002; 25(Suppl 1):S71-S73.

79. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]

80. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]

81. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]

82. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) Express. Bethesda, MD: May 14 2003. From NIH website. (Also published in JAMA. 2003; 289:2560-71.

83. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000;356:1955-64.

84. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.

85. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension. 2001; 37:12-18. [PubMed 11208750]

86. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.

87. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE). Lancet. 2002;359:995-1003.

88. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.

89. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.

90. Wing LMH, Reid CM, Ryan P, et al, for Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92.

91. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2002;40:1366-1374.

92. Hager WD, Davis BR, Riba A, et al, for the Survival and Ventricular Enlargement (SAVE) Investigators. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: the SAVE Study Experience. Am Heart J. 1998;135:406-13.

93. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.

94. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-2. [PubMed 12502624]

95. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41. [IDIS 494836] [PubMed 12622600]

96. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol. 2001;38:2101-2113.

97. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982; 247:1707-14.

98. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the Capricorn randomized trial. Lancet. 2001; 357:1385-90. [IDIS 465816] [PubMed 11356434]

99. Pfeffer MA, Braunwald E, Moye LA et al for the SAVE Investigators Group. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargment Trial. N Engl J Med. 1992; 327:669. [IDIS 301129] [PubMed 1386652]

100. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011-53.

101. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003; 290:199-206. [PubMed 12851274]

102. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

103. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39(Suppl 2):S1-246. [PubMed 11904577]

104. Reviewers’ comments (personal observations) on the Thiazides General Statement 40:28.

105. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. [PubMed 15286277]

107. Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets prescribing information. New York, NY; 2007 Dec.

108. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. [IDIS 531054] [PubMed 15811979]

109. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. Editorial. [IDIS 531056] [PubMed 15811986]

110. Leenen FHH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium-channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Hypertension. 2006; 48:374-84. [PubMed 16864749]

111. Messerli FH, Staessen JA. Amlodipine better than lisinopril: how one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006; 48:359-61. Editorial. [PubMed 16894055]

112. Daiichi Sankyo, Inc. Azor (amlodipine and olmesartan medoxomil) tablets prescribing information. Parsippany, NJ; 2008 Oct.

113. Novartis Pharmaceuticals Corp. Exforge (amlodipine and valsartan) tablets prescribing information. East Hanover, NJ; 2008 Jul.

b. AHFS drug information 2007. McEvoy GK, ed. Nifedipine. Bethesda, MD: American Society of Hospital Pharmacists; 2007:1889-96.

Hide
(web5)